FIELD: pharmaceutics.
SUBSTANCE: invention relates to a class of tricyclic compounds and their use as an agonist of the sphingosine 1-phosphate receptor type 1 (S1P1). In particular, the present invention relates to a new compound represented by formula (II), its tautomer and a pharmacologically acceptable salt, wherein the values of X, A, B, D, R1-R3 are defined in the claim.
EFFECT: compounds are designed to treat diseases associated with S1P1, such as autoimmune diseases, multiple sclerosis, bronchial asthma, and stroke.
47 cl, 2 tbl, 56 ex
Title | Year | Author | Number |
---|---|---|---|
HYDROXYPURINE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2685417C1 |
QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
PYRAZOLO [3,4-C] PYRIDINES AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2638116C2 |
CYCLOHEXANE DERIVATIVE AND ITS PHARMACEUTICAL USE | 2009 |
|
RU2478621C2 |
TETRAHYDROIMIDAZO[1,5-D][1,4]OXAZEPINE DERIVATIVE | 2014 |
|
RU2659219C2 |
AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | 2011 |
|
RU2576036C2 |
SUBSTITUTED INDOLE COMPOUNDS AS REDUCING REGULATORS OF ESTROGEN RECEPTORS | 2017 |
|
RU2722441C2 |
DERIVATIVE BASED ON DIHYDROPYRIMIDO-RING AS HBV INHIBITOR | 2015 |
|
RU2693897C2 |
BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
Authors
Dates
2021-09-08—Published
2017-07-21—Filed